ABSCIENCES (EPA:AB) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
ABSCIENCES

BRIEF

published on 07/24/2025 at 08:01, 4 months 11 days ago

AB Science Gains Approval for Phase 3 ALS Masitinib Study Across Europe

Phase 3 Trial ALS AB Science Masitinib European Approval
PRESS RELEASE

published on 07/24/2025 at 07:56, 4 months 11 days ago

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
AB Science receives approval from European countries to initiate Phase 3 study of masitinib in ALS following protocol validation by EMA and FDA

Phase 3 Study ALS AB Science Masitinib EMA
BRIEF

published on 07/08/2025 at 08:06, 4 months 27 days ago

AB Science Completes EUR 1.925 Million Private Placement

Private Placement Share Issuance Biotech Funding AB Science AB8939 Program
PRESS RELEASE

published on 07/08/2025 at 08:01, 4 months 27 days ago

AB Science announces the successful completion of a EUR 1.925 million private placement
AB Science successfully completes EUR 1.925 million private placement to finance ongoing activities and focus on AB8939 program development. New shares to be admitted to trading on Euronext Paris

Private Placement Euronext Paris AB Science AB8939 Program EUR 1.925 Million
BRIEF

published on 07/04/2025 at 08:06, 5 months ago

AB Science: Green light for phase 3 study of masitinib in prostate cancer

Phase 3 AB Science Masitinib Prostate Cancer FDA And EMA
BRIEF

published on 07/01/2025 at 10:13, 5 months 3 days ago

Results of the AB Science General Meeting

Share Capital Voting Rights Resolutions General Assembly AB Science
BRIEF

published on 06/30/2025 at 08:08, 5 months 4 days ago

AB Science Secures Two-Year Loan Repayment Deferment

Financial Strategy Debt Restructuring AB Science Loan Deferment Creditors Agreement
PRESS RELEASE

published on 06/30/2025 at 08:03, 5 months 4 days ago

AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
AB Science reaches agreement with financial creditors to defer loan repayment terms by 24 months, leading to investment in R&D. Negotiations ongoing for postponement of EIB COVID loan repayment

Financial Creditors R&D Investment Loan Repayment AB Science EIB COVID Loan
BRIEF

published on 06/23/2025 at 08:08, 5 months 11 days ago

Masitinib Shows Promise as Alzheimer's Treatment in Peer-Reviewed Study

Alzheimer's Disease Phase 3 Study Neuroprotection Masitinib Cognitive Enhancement
PRESS RELEASE

published on 06/23/2025 at 08:03, 5 months 11 days ago

AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
New peer-reviewed data supports masitinib's potential for treating Alzheimer's disease through cognitive enhancement and neuroprotection. Phase 3 study authorized by FDA and key EU countries

Alzheimer's Disease Phase 3 Study Neuroprotection Masitinib Cognitive Enhancement

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 53 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 58 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 28 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 23 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 28 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 57 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 37 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 2 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 13 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 17 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 28 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 43 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 43 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 27 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE